You are here: Industry Insights > mRNA-1273

News List

US CDC committee recommends Moderna’s Covid-19 vaccine for use in adults pharmaceutical-technology
December 22, 2020
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of Moderna’s Covid-19 vaccine in adults under the Emergency Use Authorisation (EUA) issued by the US Food and Drug ...
European Commission to purchase additional 80 mn doses of Moderna’s COVID-19 vaccine expresspharma
December 21, 2020
Moderna announced that the European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate, bringing its confirmed order commitment to 160 million doses.
US FDA gives EUA to Moderna’s mRNA vaccine against COVID-19 expresspharma
December 21, 2020
Total of 200 million doses ordered by the US government to date, approximately 20 million doses will be delivered by the end of December 2020.
US FDA Advisory Committee supports EUA for Moderna’s COVID-19 vaccine expresspharma
December 18, 2020
Moderna confirmed that the US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an emergency use authorisation (EUA) for the company’s COVID-19 vaccine candidate ...
US FDA report finds Moderna’s Covid-19 vaccine to have no specific safety concerns pharmaceutical-technology
December 16, 2020
The US Food and Drug Administration (FDA) in its briefing document stated that Moderna’s experimental Covid-19 vaccine, mRNA-1273, is 94.1% effective in preventing symptomatic Covid-19.
Moderna signs supply agreement with Singapore for COVID-19 vaccine expresspharma
December 15, 2020
Moderna recently announced data showing that mRNA-1273 remains stable at 2° to 8°C (36° to 46°F), the temperature of a standard home or medical refrigerator, for 30 days.
US orders additional 100 mn doses of Moderna’s COVID-19 vaccine expresspharma
December 14, 2020
Total of 200 million doses ordered by the US government to date, it retains option to purchase up to an additional 300 million doses.
Moderna announces dosing of first adolescent participants in Phase II-III trials of COVID-19 vaccine expresspharma
December 11, 2020
Moderna announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, the company’s vaccine candidate against COVID-19, in adolescents ages 12 to less than 18.
UK becomes first country to initiate Covid-19 vaccination pharmaceutical-technology
December 09, 2020
The United Kingdom (UK) has started administering the Covid-19 vaccine, developed by Pfizer and its German partner BioNTech, outside a clinical trial, becoming the first country in the world to administer the new vaccine.
NIAID study shows Moderna’s Covid-19 vaccine provides three-month immunity pharmaceutical-technology
December 07, 2020
Researchers at the National Institute for Allergies and Infectious Diseases (NIAID) have reported that Moderna’s Covid-19 vaccine, mRNA-1273, caused the human immune system to produce potent antibodies that endure for at least three months.

Previous page 1 2 3 4 5 6 Next page